Shares of Insulet Co. (NASDAQ:PODD) have been assigned an average rating of “Hold” from the nineteen ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $164.67.
Several analysts recently commented on PODD shares. Morgan Stanley boosted their price target on Insulet from $148.00 to $181.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Raymond James boosted their price objective on Insulet from $158.00 to $213.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Piper Jaffray Companies boosted their price objective on Insulet from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. Stifel Nicolaus assumed coverage on Insulet in a research note on Tuesday, October 22nd. They issued a “hold” rating and a $163.00 price objective on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on Insulet from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th.
PODD stock traded up $6.86 during trading on Friday, hitting $212.27. The company had a trading volume of 299,476 shares, compared to its average volume of 469,447. The company has a fifty day moving average price of $187.12 and a two-hundred day moving average price of $165.85. The company has a current ratio of 7.01, a quick ratio of 6.21 and a debt-to-equity ratio of 6.55. The company has a market cap of $12.70 billion, a P/E ratio of 816.45 and a beta of 0.77. Insulet has a fifty-two week low of $80.43 and a fifty-two week high of $207.28.
Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its holdings in shares of Insulet by 382.1% during the 4th quarter. Renaissance Technologies LLC now owns 499,900 shares of the medical instruments supplier’s stock valued at $85,583,000 after acquiring an additional 396,200 shares in the last quarter. Eagle Asset Management Inc. grew its position in Insulet by 86.3% in the 3rd quarter. Eagle Asset Management Inc. now owns 709,266 shares of the medical instruments supplier’s stock worth $116,979,000 after purchasing an additional 328,620 shares during the period. Carillon Tower Advisers Inc. boosted its stake in shares of Insulet by 97.3% during the 3rd quarter. Carillon Tower Advisers Inc. now owns 524,087 shares of the medical instruments supplier’s stock worth $86,438,000 after acquiring an additional 258,424 shares during the last quarter. Beacon Investment Advisory Services Inc. boosted its stake in shares of Insulet by 2,469.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 267,269 shares of the medical instruments supplier’s stock worth $45,756,000 after acquiring an additional 256,869 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new position in shares of Insulet during the 4th quarter worth $38,728,000.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Featured Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.